Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC
The study was to evaluate the safety, PFS and ORR of icotinib/dihydroaremisinin (DHA)-based combination therapy in EGFR-mutated, advanced NSCLC patients who have gradually progressed disease after first-line icotinib treatment.
EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma
DRUG: Icotinib combined dihydroaremisinin
Progress Free Survival, 18 months|Objective response rate, 18 months
Overall Survival, 24 months
The study was to evaluate the safety, PFS and ORR of icotinib/dihydroaremisinin (DHA)-based combination therapy in EGFR-mutated, advanced NSCLC patients who have gradually progressed disease after first-line icotinib treatment.